In Fiscal Year 2025 (FY25), Massachusetts reinforced its position as the global hub for life sciences innovation, driven in part by the Massachusetts Life Sciences Center’s (MLSC) Tax Incentive program. The program supports companies expanding research, development, manufacturing, and commercialization efforts across the Commonwealth while creating long-term, high-quality jobs.
During FY25, the Healey-Driscoll Administration and the MLSC announced two rounds of Tax Incentive awards, an initial round and a supplemental mini-round enabled by the Mass Leads Act, which increased the program’s annual statutory cap. Together, the awards totaled $40 million and supported the creation of nearly 2,000 new jobs statewide.
The 48 awardee companies reflect the diversity of Massachusetts’ life sciences ecosystem, spanning drug discovery, diagnostics, medical devices, and biomanufacturing. Notably, 34 companies expanded operations in communities outside of Boston and Cambridge, accounting for 68 percent of projected job creation and underscoring the program’s role in driving regional economic growth.
Key expansion highlights included Sartorius Stedim Biotech, which opened a new Center for Bioprocess Innovation in Marlborough to support collaborative bioprocess workflows, and Astellas Pharma, which opened its Astellas Life Sciences Center in Cambridge, further strengthening its Massachusetts presence.
Since its inception, the MLSC’s Tax Incentive program has supported more than 20,700 jobs statewide, leveraging public investment to spur private-sector growth and reinforce Massachusetts as the best place in the world to innovate, work, and grow.
The MLSC recently opened a new round of its Tax Incentive program to support life sciences companies of all sizes looking to expand efforts in Massachusetts. Click here to learn more about the program and register for an upcoming info session.
